Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374931 | 0.76 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL170196 | 0.76 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL2996550 | 0.76 | PDE10A (0.40) | RAB9ANPC1CYP1A2MEN1KMT2A | |
| SCHEMBL1434260 | 0.76 | RAB9A (0.46) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL8637618 | 0.74 | GSTP1 (0.40) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL16719690 | 0.74 | METAP1 (0.45) | RAB9ANPC1CYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL31243061 | 0.74 | ALDH1A1 (0.63) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL10866984 | 0.74 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL34463709 | 0.74 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL30883993 | 0.74 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | claimed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | claimed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | claimed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | claimed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
| US-6107307-A | PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 2000-08-22 | — | — | US | claimed |
| US-4895856-A | ANTISPASMODIC, PANCREATITIS, NERVOUS SYSTEM DISORDERS | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1990-01-23 | — | — | US | claimed |
| EP-3357904-B1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | PRECIGEN INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | GENZYME CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | disclosed |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2020-04-28 | — | — | US | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3357904-A1 | CHIRAL DIACHYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | Intrexon Corporation (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | disclosed |
| US-6660408-B1 | Having diarylamino substituted diaryl, triaryl or tetraaryl light emitting, electron transporting material; high performance and luminance | NEC CORPORATION (JP) | 2003-12-09 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171507-A1 | SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITORS | UGCG, UGGT1, DPAGT1 | RAB9A 1520/4885NPC1 137/4885CYP3A4 3041/4885 |
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | RAB9A 1478/4885NPC1 122/4885CYP3A4 341/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | RAB9A 1478/4885NPC1 122/4885CYP3A4 341/4885 |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | RAB9A 1193/4885NPC1 1817/4885CYP3A4 4269/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | RAB9A 4537/4885NPC1 2592/4885CYP3A4 2691/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | RAB9A 2814/4885NPC1 1925/4885CYP3A4 3946/4885 |
| US-10633361-B2 | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, CRYZ, TCF12 | RAB9A 4537/4885NPC1 2592/4885CYP3A4 2691/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | RAB9A 1258/4885NPC1 86/4885CYP3A4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.